Prescient Therapeutics Ltd
ASX:PTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Prescient Therapeutics Ltd
Cash & Cash Equivalents
Prescient Therapeutics Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prescient Therapeutics Ltd
ASX:PTX
|
Cash & Cash Equivalents
AU$9.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
18%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash & Cash Equivalents
$129.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
1%
|
|
|
CSL Ltd
ASX:CSL
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Cash & Cash Equivalents
AU$20.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash & Cash Equivalents
AU$141.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash & Cash Equivalents
AU$120.7m
|
CAGR 3-Years
92%
|
CAGR 5-Years
38%
|
CAGR 10-Years
29%
|
|
Prescient Therapeutics Ltd
Glance View
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).
See Also
What is Prescient Therapeutics Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
9.7m
AUD
Based on the financial report for Dec 31, 2025, Prescient Therapeutics Ltd's Cash & Cash Equivalents amounts to 9.7m AUD.
What is Prescient Therapeutics Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
18%
Over the last year, the Cash & Cash Equivalents growth was 53%. The average annual Cash & Cash Equivalents growth rates for Prescient Therapeutics Ltd have been -23% over the past three years , -12% over the past five years , and 18% over the past ten years .
